Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Accumulation of Mutational Load at the Edges of a Species Range.

Willi Y, Fracassetti M, Zoller S, Van Buskirk J.

Mol Biol Evol. 2018 Apr 1;35(4):781-791. doi: 10.1093/molbev/msy003.

PMID:
29346601
2.

Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia.

Butler K, Day C, Sutherland R, van Buskirk J, Breen C, Burns L, Larney S.

Int J Drug Policy. 2017 Sep;47:102-106. doi: 10.1016/j.drugpo.2017.07.008. Epub 2017 Aug 5.

PMID:
28789820
3.

Is bigger really better? Relative and absolute body size influence individual growth rate under competition.

Van Buskirk J, Cereghetti E, Hess JS.

Ecol Evol. 2017 Apr 17;7(11):3745-3750. doi: 10.1002/ece3.2978. eCollection 2017 Jun.

4.

Spatially heterogeneous selection in nature favors phenotypic plasticity in anuran larvae.

Van Buskirk J.

Evolution. 2017 Jun;71(6):1670-1685. doi: 10.1111/evo.13236. Epub 2017 Apr 13.

PMID:
28346658
5.

The recovery of online drug markets following law enforcement and other disruptions.

Van Buskirk J, Bruno R, Dobbins T, Breen C, Burns L, Naicker S, Roxburgh A.

Drug Alcohol Depend. 2017 Apr 1;173:159-162. doi: 10.1016/j.drugalcdep.2017.01.004. Epub 2017 Feb 20.

PMID:
28259089
6.

Trends in new psychoactive substances from surface and "dark" net monitoring.

Van Buskirk J, Griffiths P, Farrell M, Degenhardt L.

Lancet Psychiatry. 2017 Jan;4(1):16-18. doi: 10.1016/S2215-0366(16)30405-9. No abstract available.

PMID:
28012470
7.

I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances.

Matthews A, Sutherland R, Peacock A, Van Buskirk J, Whittaker E, Burns L, Bruno R.

Int J Drug Policy. 2017 Feb;40:44-49. doi: 10.1016/j.drugpo.2016.11.004. Epub 2016 Dec 8.

PMID:
27939599
8.

Corrigendum to "Characterising dark net marketplace purchasers in a sample of regular psychostimulant users" [International Journal of Drug Policy 35 (2016) 32-37].

Van Buskirk J, Roxburgh A, Bruno R, Naicker S, Lenton S, Sutherland R, Whittaker E, Sindicich N, Matthews A, Butler K, Burns L.

Int J Drug Policy. 2017 Jan;39:140. doi: 10.1016/j.drugpo.2016.11.001. Epub 2016 Nov 30. No abstract available.

PMID:
27914792
9.

Who sells what? Country specific differences in substance availability on the Agora cryptomarket.

Van Buskirk J, Naicker S, Roxburgh A, Bruno R, Burns L.

Int J Drug Policy. 2016 Sep;35:16-23. doi: 10.1016/j.drugpo.2016.07.004. Epub 2016 Jul 20.

PMID:
27520115
10.

Quantitative Genetic Architecture at Latitudinal Range Boundaries: Reduced Variation but Higher Trait Independence.

Paccard A, Van Buskirk J, Willi Y.

Am Nat. 2016 May;187(5):667-77. doi: 10.1086/685643. Epub 2016 Mar 3.

PMID:
27104998
11.

Characterising dark net marketplace purchasers in a sample of regular psychostimulant users.

Van Buskirk J, Roxburgh A, Bruno R, Naicker S, Lenton S, Sutherland R, Whittaker E, Sindicich N, Matthews A, Butler K, Burns L.

Int J Drug Policy. 2016 Sep;35:32-7. doi: 10.1016/j.drugpo.2016.01.010. Epub 2016 Jan 18. Erratum in: Int J Drug Policy. 2017 Jan;39:140.

PMID:
26872846
12.

A response to Dolliver's "Evaluating drug trafficking on the Tor network".

Van Buskirk J, Roxburgh A, Naicker S, Burns L.

Int J Drug Policy. 2015 Nov;26(11):1126-7. doi: 10.1016/j.drugpo.2015.07.001. Epub 2015 Jul 10. No abstract available.

PMID:
26256939
13.

The relative importance of prey-borne and predator-borne chemical cues for inducible antipredator responses in tadpoles.

Hettyey A, Tóth Z, Thonhauser KE, Frommen JG, Penn DJ, Van Buskirk J.

Oecologia. 2015 Nov;179(3):699-710. doi: 10.1007/s00442-015-3382-7. Epub 2015 Jul 11.

PMID:
26163350
14.

Isocline analysis of competition predicts stable coexistence of two amphibians.

Gazzola A, Van Buskirk J.

Oecologia. 2015 May;178(1):153-9. doi: 10.1007/s00442-015-3273-y. Epub 2015 Feb 28.

PMID:
25722192
15.

The rise of new psychoactive substance use in Australia.

Burns L, Roxburgh A, Matthews A, Bruno R, Lenton S, Van Buskirk J.

Drug Test Anal. 2014 Jul-Aug;6(7-8):846-9. doi: 10.1002/dta.1626. Epub 2014 Mar 5.

PMID:
24599890
16.

Incipient habitat race formation in an amphibian.

Van Buskirk J.

J Evol Biol. 2014 Mar;27(3):585-92. doi: 10.1111/jeb.12327. Epub 2014 Feb 3.

17.

Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia.

Burns L, Roxburgh A, Bruno R, Van Buskirk J.

Drug Test Anal. 2014 Jul-Aug;6(7-8):840-5. doi: 10.1002/dta.1613. Epub 2014 Feb 12. Review.

PMID:
24574080
18.

The closure of the Silk Road: what has this meant for online drug trading?

Van Buskirk J, Roxburgh A, Farrell M, Burns L.

Addiction. 2014 Apr;109(4):517-8. doi: 10.1111/add.12422. Epub 2014 Jan 8. No abstract available.

PMID:
24397386
19.

Drift load in populations of small size and low density.

Willi Y, Griffin P, Van Buskirk J.

Heredity (Edinb). 2013 Mar;110(3):296-302. doi: 10.1038/hdy.2012.86. Epub 2012 Dec 5.

20.

Non-interactive multiple predator effects on tadpole survival.

Ramos O, Van Buskirk J.

Oecologia. 2012 Jun;169(2):535-9. doi: 10.1007/s00442-011-2208-5. Epub 2011 Dec 8.

PMID:
22159918
21.

Predator-induced changes in metabolism cannot explain the growth/predation risk tradeoff.

Steiner UK, Van Buskirk J.

PLoS One. 2009 Jul 7;4(7):e6160. doi: 10.1371/journal.pone.0006160.

22.

Getting in shape: adaptation and phylogenetic inertia in morphology of Australian anuran larvae.

Van Buskirk J.

J Evol Biol. 2009 Jun;22(6):1326-37. doi: 10.1111/j.1420-9101.2009.01750.x. Epub 2009 Apr 23.

23.

The fitness costs of developmental canalization and plasticity.

Van Buskirk J, Steiner UK.

J Evol Biol. 2009 Apr;22(4):852-60. doi: 10.1111/j.1420-9101.2009.01685.x. Epub 2009 Feb 14.

24.
25.

Environmental stress and the costs of whole-organism phenotypic plasticity in tadpoles.

Steiner UK, VAN Buskirk J.

J Evol Biol. 2008 Jan;21(1):97-103. doi: 10.1111/j.1420-9101.2007.01463.x. Epub 2007 Nov 22.

26.
27.

Genetic isolation of fragmented populations is exacerbated by drift and selection.

Willi Y, Van Buskirk J, Schmid B, Fischer M.

J Evol Biol. 2007 Mar;20(2):534-42.

28.

The change in quantitative genetic variation with inbreeding.

Van Buskirk J, Willi Y.

Evolution. 2006 Dec;60(12):2428-34.

PMID:
17263106
29.
30.

Habitat specialization and adaptive phenotypic divergence of anuran populations.

Van Buskirk J, Arioli M.

J Evol Biol. 2005 May;18(3):596-608.

31.

A comparative analysis of predator-induced plasticity in larval Triturus newts.

Schmidt BR, Van Buskirk J.

J Evol Biol. 2005 Mar;18(2):415-25.

33.
34.
35.

Influence of tail shape on tadpole swimming performance.

Van Buskirk J, McCollum SA.

J Exp Biol. 2000 Jul;203(Pt 14):2149-58.

36.

NATURAL SELECTION FOR ENVIRONMENTALLY INDUCED PHENOTYPES IN TADPOLES.

Van Buskirk J, McCollum SA, Werner EE.

Evolution. 1997 Dec;51(6):1983-1992. doi: 10.1111/j.1558-5646.1997.tb05119.x.

37.

COSTS AND BENEFITS OF A PREDATOR-INDUCED POLYPHENISM IN THE GRAY TREEFROG HYLA CHRYSOSCELIS.

McCollum SA, Van Buskirk J.

Evolution. 1996 Apr;50(2):583-593. doi: 10.1111/j.1558-5646.1996.tb03870.x.

PMID:
28568914
38.

Density-dependent population dynamics in larvae of the dragonfly Pachydiplax longipennis: a field experiment.

Van Buskirk J.

Oecologia. 1987 May;72(2):221-225. doi: 10.1007/BF00379272.

PMID:
28311544
39.

Aminomalonic acid: identification in Escherichia coli and atherosclerotic plaque.

Van Buskirk JJ, Kirsch WM, Kleyer DL, Barkley RM, Koch TH.

Proc Natl Acad Sci U S A. 1984 Feb;81(3):722-5.

40.

beta-Carboxyaspartic acid.

Koch TH, Christy MR, Barkley RM, Sluski R, Bohemier D, Van Buskirk JJ, Kirsch WM.

Methods Enzymol. 1984;107:563-75. No abstract available.

PMID:
6390094
41.

gamma-Carboxyglutamic acid in eukaryotic and prokaryotic ribosomes.

Van Buskirk JJ, Kirsch WM.

Biochem Biophys Res Commun. 1978 Jun 29;82(4):1329-31. No abstract available.

PMID:
212042
42.

The occurrence of gamma-carboxyglutamic acid in mammalian ribosomes.

Van Buskirk JJ, Kirsch WM.

Biochem Biophys Res Commun. 1978 Feb 28;80(4):1033-8. No abstract available.

PMID:
205212
43.

Screening of human brain tumors for SV40-related T antigen.

Tabuchi K, Kirsch WM, Low M, Gaskin D, Van Buskirk J, Maa S.

Int J Cancer. 1978 Jan 15;21(1):12-7.

PMID:
203540
44.

The metabolism of the glioblastoma: pathobiological correlates.

Kirsch WM, Tucker WS, Tabuchi K, Fink LM, Van Buskirk JJ, Low M.

Clin Neurosurg. 1978;25:310-25. No abstract available.

PMID:
213224
45.

Immunocytochemical evidence of SV 40-related T antigen in two human brain tumours of ependymal origin.

Tabuchi K, Kirsch WM, Van Buskirk JJ.

Acta Neurochir (Wien). 1978;43(3-4):239-49.

PMID:
212932
46.

[Screening of human brain tumors for SV40-related T antigen (author's transl)].

Tabuchi K, Nishimoto A, Kirsch WM, Van Buskirk JJ.

Neurol Med Chir (Tokyo). 1977 Sep;17(5 Pt 2):383-90. Japanese. No abstract available.

PMID:
74039
47.

The biologic basis of malignant brain tumor therapy.

Kirsch WM, Van Buskirk JJ, Schulz DW, Tabuchi K.

Adv Neurol. 1976;15:301-13. Review. No abstract available.

PMID:
180778
48.

Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.

Kirsch WM, Schulz D, Van Buskirk JJ, Young HE.

J Med. 1974;5(1):69-82. No abstract available.

PMID:
4364886
49.

Loss of hepatoma ribosomal RNA during warfarin therapy.

Van Buskirk JJ, Kirsch WM.

Biochem Biophys Res Commun. 1973 May 15;52(2):562-8. No abstract available.

PMID:
4351140
50.

Anaerobic energy metabolism in brain tumors.

Kirsch WM, Schulz Q, Van Buskirk J, Nakane P.

Prog Exp Tumor Res. 1972;17:163-91. Review. No abstract available.

PMID:
4343199

Supplemental Content

Loading ...
Support Center